Expansion of Peptide Manufacturing Facilities
CordenPharma is embarking on a monumental journey with an investment exceeding €1 billion in the next three years. This ambitious plan encompasses the construction and expansion of various peptide manufacturing facilities across Europe and the US, reinforcing its commitment to innovation in peptide development.
Investment in Switzerland
Among these initiatives, CordenPharma will invest over €500 million to establish a state-of-the-art greenfield manufacturing site located near Basel, Switzerland. This facility will focus on small to large-scale peptide development, ensuring that CordenPharma maintains its edge as a leader in the biotechnology and pharmaceutical sectors.
Strategic Location Advantages
The selection of the Basel region for the new plant is strategic. This area offers significant advantages such as efficient infrastructure for material handling and established utilities necessary for advanced peptide production. Additionally, the site's proximity to major transportation networks guarantees optimal logistics.
Access to a Skilled Workforce
Another prominent benefit of this location is the access to a talent pool. Located close to one of the leading biotech hubs in Europe, CordenPharma can tap into a well-educated workforce, ensuring the company has the necessary expertise to operate successfully.
Sustainable Operations
Sustainability is at the heart of this new development. The surrounding industrial park supports sustainable practices, featuring closed-loop energy systems and innovative waste management solutions. This aligns with CordenPharma's commitment to achieving net-zero operational impact in the long term.
Production Capabilities and Future Plans
This significant investment will incorporate multiple manufacturing lines optimized for both small and large-scale peptide production. The facility will be equipped with Solid Phase Peptide Synthesis (SPPS) reactors, designed to handle GLP-1 and non-GLP-1 peptide projects, up to a total capacity of 5,000 liters. The facilities will incorporate cutting-edge automation and digitalization to meet rigid compliance standards.
Job Creation and Economic Impact
With construction expected to begin soon, CordenPharma projects the creation of over 300 jobs, significantly contributing to the local economy and fostering innovation in the region.
Expansions in Colorado
In tandem with developments in Switzerland, CordenPharma is also advancing its facility in Colorado. This includes both increasing the capacity of existing production lines and developing new sites, ultimately aiming to boost total reactor capacity to over 42,000 liters by the target date of 2028.
Leadership Perspectives on Expansion
Dr. Michael Quirmbach, President & CEO of CordenPharma Group, expressed enthusiasm about the new facility near Basel, underscoring that it is designed to meet the increasing demand for innovative peptide medicines. The flexible manufacturing capabilities will enhance CordenPharma's service offerings to its clients.
Judith Charpentier, from the Flagship Fund, also highlighted the importance of this expansion for ensuring wider access to life-saving peptide medications. Her statements emphasize the commitment to seamlessly integrating cutting-edge technology with necessary investments in infrastructure.
About CordenPharma
CordenPharma serves as a pivotal CDMO (Contract Development and Manufacturing Organization) partner for biotech and pharmaceutical innovators globally. The company supports drug development by providing comprehensive, end-to-end service solutions from clinical phases through to commercialization.
With a focus on complex modalities such as peptides and oligonucleotides, CordenPharma’s capabilities extend to sterile injectables and customized excipients. The company operates across 11 strategically located facilities in Europe and North America, showcasing a robust workforce that drove sales to €854 million in the preceding financial year.
Frequently Asked Questions
What is CordenPharma's recent investment about?
CordenPharma is investing over €1 billion to build and expand peptide manufacturing facilities across Europe and the US, enhancing its production capabilities.
Why was Switzerland chosen for the new facility?
The Basel region offers logistical advantages, access to a skilled workforce, and sustainable operational capabilities, making it an ideal location for the new plant.
How many jobs will the new facility create?
The new manufacturing site in Switzerland is expected to generate over 300 new jobs, contributing to local economic growth.
What technologies will be used in the new facility?
The facility will feature Solid Phase Peptide Synthesis (SPPS) reactors with advanced automation and digital technologies, ensuring compliance with high standards.
What are CordenPharma's core service offerings?
CordenPharma provides extensive CDMO services, focusing on peptides, oligonucleotides, sterile injectables, and small molecules, supporting different phases of drug development.
